Ilias P Doulamis1, Konstantinos S Mylonas2, Christos E Kalfountzos3, Danny Mou4, Huzaifa Haj-Ibrahim5, Dimitrios Nasioudis6. 1. Society of Junior Doctors, Athens, Greece. 2. Society of Junior Doctors, Athens, Greece; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Society of Junior Doctors, Athens, Greece; Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 4. Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 6. Society of Junior Doctors, Athens, Greece. Electronic address: dnasioudis@sni.gr.
Abstract
BACKGROUND: Pancreatic mucinous cystadenocarcinoma is a rare malignancy. Our aim was to investigate the demographic, pathological characteristics, treatment modalities and survival of patients with mucinous cystadenocarcinoma via the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database analysis. MATERIALS AND METHODS: This was a retrospective study of SEER database's records on patients with mucinous cystadenocarcinoma diagnosed from 1988 to 2012. Primary outcome measures were clinico-pathological characteristics, observed and disease-specific survival. RESULTS: A total of 507 patients were identified. Median age at diagnosis was 67 years and most patients were female (68.4%). The tumors were mainly low grade (82.9%, grade I-II) and frequently localized (42.8%) in the body/tail of the pancreas (45.6%). According to Kaplan-Meier curves observed survival was 111 months (95%CI: 82.5, 139.5) vs 14 months (95% CI: 10.9, 17.1) vs 4 months (95%CI: 2.9, 5.1) for patients with localized, regional and distant disease, respectively. One-year disease-specific survival for patients with localized disease was 90.1%, vs. 56.7% for those with regional and 18.7% with distant tumor spread. CONCLUSIONS: Mucinous cystadenocarcinomas tend to be low grade tumors, localized to the pancreatic body/tail. Surgery as the primary therapeutic intervention and tumor stage are independent predictors of disease-specific survival.
BACKGROUND:Pancreatic mucinous cystadenocarcinoma is a rare malignancy. Our aim was to investigate the demographic, pathological characteristics, treatment modalities and survival of patients with mucinous cystadenocarcinoma via the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database analysis. MATERIALS AND METHODS: This was a retrospective study of SEER database's records on patients with mucinous cystadenocarcinoma diagnosed from 1988 to 2012. Primary outcome measures were clinico-pathological characteristics, observed and disease-specific survival. RESULTS: A total of 507 patients were identified. Median age at diagnosis was 67 years and most patients were female (68.4%). The tumors were mainly low grade (82.9%, grade I-II) and frequently localized (42.8%) in the body/tail of the pancreas (45.6%). According to Kaplan-Meier curves observed survival was 111 months (95%CI: 82.5, 139.5) vs 14 months (95% CI: 10.9, 17.1) vs 4 months (95%CI: 2.9, 5.1) for patients with localized, regional and distant disease, respectively. One-year disease-specific survival for patients with localized disease was 90.1%, vs. 56.7% for those with regional and 18.7% with distant tumor spread. CONCLUSIONS:Mucinous cystadenocarcinomas tend to be low grade tumors, localized to the pancreatic body/tail. Surgery as the primary therapeutic intervention and tumor stage are independent predictors of disease-specific survival.
Authors: Jose M Ramia; Juan Del Rio Martín; Gerardo Blanco-Fernández; Miguel Cantalejo-Diaz; Fernando Pardo; Elena Muñoz-Forner; Alberto Carabias; Alba Manuel-Vazquez; Pedro J Hernández-Rivera; Isabel Jaén-Torrejimeno; Helga K Kälviäinen-Mejia; Fernando Rotellar-Sastre; Marina Garcés-Albir; Raquel Latorre; Texell Longoria-Dubocq; Noelia De Armas-Conde; Alejandro Serrablo-Requejo; Sara Esteban Gordillo; Luis Sabater; Mario Serradilla-Martín Journal: Gland Surg Date: 2022-05
Authors: Mariacristina Di Marco; Riccardo Carloni; Stefania De Lorenzo; Cristina Mosconi; Andrea Palloni; Elisa Grassi; Daria Maria Filippini; Angela Dalia Ricci; Alessandro Rizzo; Alessandro Di Federico; Donatella Santini; Daniela Turchetti; Claudio Ricci; Carlo Ingaldi; Laura Alberici; Francesco Minni; Rita Golfieri; Giovanni Brandi; Riccardo Casadei Journal: World J Gastrointest Oncol Date: 2020-12-15